There are currently 172 clinical trials in Reno, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Renown Regional Medical Center, Saint Mary's Regional Medical Center, Radiation Oncology Associates and Sierra Eye Associates. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Mobile Health for Adherence in Breast Cancer Patients
Recruiting
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Renown Regional Medical Center, Reno, Nevada +2 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Reducing Mental Health Disparities Among Latinxs With a Telenovela Intervention
Recruiting
The primary aim of our study is to determine the effectiveness of an transdiagnostic telenovela video intervention in reducing anxiety and depressive symptoms using a pre/post-test design with Spanish-speaking Latinxs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: La Clinica @ the UNR Psychological Services Center, Reno, Nevada
Conditions: Anxiety Disorders
A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals
Recruiting
The goal of this clinical trial is to learn if a personalized biomonitoring report-back and educational intervention in child-bearing aged men and women can reduce endocrine disrupting chemicals (EDCs) measured in urine, increase participants' understanding of environmental health (environmental health literacy; EHL), increase their readiness and behaviors to reduce exposures, and improve their well-being. The intervention includes EDC testing and exposure report-back, a self-directed online in... Read More
Gender:
ALL
Ages:
Between 18 years and 44 years
Trial Updated:
07/08/2024
Locations: Renown Health, Reno, Nevada
Conditions: Environmental Exposure
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Renown Regional Medical Center, Reno, Nevada +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Feasibility and Acceptability of Switching to E-cigarettes Among Cigarette Smokers Engaged in SUD Treatment
Recruiting
The purpose of the proposed study is to examine the feasibility of integrating a smoking harm reduction program featuring provision of e-cigarettes and tailored instructions to switch into an existing substance use disorder treatment program. This longitudinal study includes three weeks of micro-surveys delivered via text messages to evaluate the intervention's feasibility and acceptability, gather initial effectiveness data, and understand participants' lived experience of smoking and vaping wh... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/27/2024
Locations: University of Nevada, Reno, Reno, Nevada
Conditions: Tobacco Dependence Caused by Cigarettes
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
Recruiting
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/25/2024
Locations: Reno Location, Reno, Nevada
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Reno VA/Sierra Nevada Health Care, Reno, Nevada
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail PF
Recruiting
This investigation is a prospective, multicenter clinical investigation. It is anticipated that a total of 50 subjects will be enrolled at up to 5 sites. Enrollment is estimated to commence in Q4 of 2018. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System. Total duration of enrollment, 12 month follow-up and analysis is expected... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Reno Orthopedic Clinic, Reno, Nevada
Conditions: Femoral Fracture
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruiting
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Renown Regional Medical Center, Reno, Nevada +2 locations
Conditions: Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Low Grade Fallopian Tube Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Ovarian Low Grade Serous Adenocarcinoma
Connect® Myeloid Disease Registry
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Renown Regional Medical Center, Reno, Nevada
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. Cancer and its treatment can cause fatigue. Giving bupropion may improve cancer related fatigue in cancer survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Renown Regional Medical Center, Reno, Nevada +2 locations
Conditions: Be Diagnosed With Cancer and Have Completed Systemic Therapy
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Recruiting
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Renown Regional Medical Center, Reno, Nevada +2 locations
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8